Table 1.
Characteristics of study population
| Mean ± SD or n (%) |
Median (range interquartile) | |
|---|---|---|
| age at diagnosis (years) | 68.26 ± 6.34 | 68 (64, 73) |
| male | 35 (83.33) | |
| female | 7 (16.67) | |
| current/former smoker | 33 (78.57) | |
| never smoker | 9 (21.43) | |
| follow up time (days) | 1037.33 ± 430.04 | 978 (683.84, 1362) |
| FVC%a | 84.28 ± 16.33 | 83.5 (74, 95) |
| DLCO%b | 60.73 ± 17.16 | 61.5 (49, 69) |
| GAP (points)c | 3.19 ± 1.10 | 3 (3, 4) |
| deceased | 10 (23.81) | |
| pirfenidone only | 38 (90.48) | |
| pirfenidone switched to nintedanib | 4 (9.52) | |
| kurtosis | 1.27 ± 1.07 | 1.05 (0.5, 1.77) |
| skewness | 1.28 ± 0.33 | 1.29 (1.12, 1.51) |
| Mean Lung Density | − 770.77 ± 46.84 | − 779.03 (− 795.90, − 755.98) |
| HAAd | 15.31 ± 5.32 | 14.67 (11.91, 16.80) |
| Fibrotic Area% | 25.78 ± 9.16 | 24.10 (19.55, 28.94) |
aFVC Forced Vital Capacity, bDLCO Diffusing Capacity for carbon monoxide, cGAP Gender-Age-Physiology index, dHAA High attenuation areas